Sanofi-Aventis 3Q10 3Q Revenues: $10.0 billion (-5%) 3Q Earnings: $3.2 billion (+5%) YTD Revenues: $30.2 billion (+1%) YTD Earnings: $9.7 billion (+5%) Comments: Pharma sales dropped 4% for the quarter to $8.5 billion, due in part to generic Lovenox and Eloxatin in the U.S., and generic Plavix in Europe. YTD pharma sales were down 1% to $26.4 billion. Lovenox sales dropped 26% to $760 in 3Q10, with a 47% drop in U.S. sales and a 5% increase in non-U.S. markets. Vaccine revenues ro...